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Available online xxxxIndividuals with 22q11.2 Deletion Syndrome (22q11.2DS) are at substantially heightened risk for psychosis.
Thus, prevention and early intervention strategies that target the antecedents of psychosis in this high-risk
group are a clinical priority. Attention Deﬁcit Hyperactivity Disorder (ADHD) is one themost prevalent psychiat-
ric disorders in childrenwith 22q11.2DS, particularly the inattentive subtype. The aimof this studywas to test the
hypothesis that ADHD inattention symptoms predict later psychotic symptoms and/or psychotic disorder in
those with 22q11.2DS. 250 children and adolescents with 22q11.2DS without psychotic symptoms at baseline
took part in a longitudinal study. Assessmentswere performed usingwell-validated structured diagnostic instru-
ments at two time points (T1 (mean age = 11.2, SD = 3.1) and T2 (mean age = 14.3, SD = 3.6)). Inattention
symptoms at T1 were associated with development of psychotic symptoms at T2 (OR:1.2, p= 0.01) but weak
associations were found with development of psychotic disorder (OR:1.2, p = 0.15). ADHD diagnosis at T1
was strongly associated with development of psychotic symptoms at T2 (OR:4.5, p b 0.001) and psychotic disor-
der (OR:5.9, p= 0.02). Our ﬁndings that inattention symptoms and the diagnosis of ADHD are associated with
subsequent psychotic outcomes in 22q11.2DS have important clinical implications. Future studies examining
the effects of stimulant and other ADHD treatments on individuals with 22q11.2DS are warranted.
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22q11.2 Deletion Syndrome (22q11.2DS) is diagnosed typically on
the basis of its clinical presentation together with laboratory evidence
of a deletion or Copy Number Variant (CNV) at band q11.2 on chromo-
some 22. Approximately 1 in 4000 individuals are affected by
22q11.2DS, rendering this the most common chromosomal
microdeletion syndrome (McDonald-McGinn et al., 2015). While theity disorder symptoms as antecedents of later psychotic outcomes in
6/j.schres.2018.07.044
Table 1
Measures used in the sites included in the study from the International Brain and Behavior
Consortium in 22q11.2 Deletion Syndrome (IBBC).
Site Sample size Measures
Cardiff 53 CAPA
Durham, N.C. 48 C-DISC
Geneva 71 DICA. K-SADS psychosis supplement
Philadelphia 38 K-SADS, SCID
Rome 37 K-SADS
Utrecht 76 K-SADS
Abbreviations: CAPA = Child and Adolescent Psychiatric Assessment (Angold et al.,
1995), K-SADS= Schedule for Affective Disorders and Schizophrenia for School-Age Chil-
dren (Kaufman et al., 1997), SCID= Structured Clinical Interview for DSM-IV Axis I Disor-
ders (First et al., 1996), DICA= Diagnostic Interview for Children and Adolescents (Reich,
2000), C-DISC= Computerized Diagnostic Interview Schedule for Children (Shaffer et al.,
1993).
2 M. Niarchou et al. / Schizophrenia Research xxx (2018) xxx–xxxmicrodeletions range in size from 0.7 to 3 million base (MB) pairs, the
majority of patients (~85%) have a 3 MB deletion (Guna et al., 2015).
The physical, cognitive and psychiatric manifestations associated with
22q11.2DS are variable and involve multiple systems including im-
mune, cardiac, palatal, gastrointestinal and endocrine deﬁcits, regard-
less of deletion size (Shprintzen, 2008). An association between the
22q11.2 deletion and psychosis has long been recognised (Rees et al.,
2014). Approximately 1 in 4 individuals with 22q11.2DS develop
schizophrenia (e.g. (Monks et al., 2014)) and around 1 in 100 individ-
uals with schizophrenia have been found to carry the 22q11.2 deletion
(Costain et al., 2013). This means that those with 22q11.2DS are at sub-
stantially elevated risk of developing schizophrenia spectrum disorders
with an onset typically occurring after mid-late adolescence.
Numerous studies of individuals with 22q11.2DS have observed a
range of psychiatric and cognitive problems in childhood and adoles-
cence; that is, prior to the typical age of onset for psychosis. These in-
clude anxiety disorders, Autism Spectrum Disorder (ASD) and
intellectual disability (Schneider et al., 2014). AttentionDeﬁcit Hyperac-
tivity Disorder (ADHD) is one of the most prevalent psychiatric disor-
ders in childhood occurring in around 40% of individuals with
22q11.2DS (Niarchou et al., 2014; Schneider et al., 2014). Although
the psychosis phenotype in 22q11.2DS is largely similar to individuals
without the deletion (e.g., (Bassett et al., 2005)), the ADHD phenotype
differs. Those with 22q11.2DS show more pronounced inattention
symptoms than individuals with ADHD from clinically ascertained and
general population samples (e.g., (Niarchou et al., 2015)). Attentional
impairments are a central characteristic of schizophrenia and ADHD.
Also, inattention symptoms have been shown to be antecedents of psy-
chosis in studies of childhood-onset schizophrenia (e.g., (Alaghband-
Rad et al., 1995)) as well as in studies of individuals with prodromal
clinical psychosis (Pukrop et al., 2007) and of thosewith subclinical psy-
chotic symptoms (e.g., (Niarchou et al., 2013)). Prior cross-sectional in-
vestigation also suggests that ADHD inattention symptoms are
associated with subthreshold psychosis in 22q11.2DS (Niarchou et al.,
2017a). To address the hypothesis that ADHD is an antecedent of psy-
chosis in children and adolescents with 22q11.2 DS, we employed the
ﬁrst multisite and largest longitudinal study of 22q11.2DS to date to in-
vestigate this question. Here, in a sample that was ﬁrst assessed at age
18 years or younger, we investigatewhether childhood ADHDdiagnosis
and inattention symptoms are early indicators of psychosis. We also as-
sess whether changes in inattention symptom levels and ADHD diagno-
sis are associated with later psychosis.2. Method
2.1. 22q11.2DS sample
The International 22q11.2 Deletion Syndrome Brain Behavior Con-
sortium (IBBC) was established in 2013 with the aim of harmonizing
existing well-characterized cohorts of participants with 22q11.2DS
with both phenotypic and genotypic data available (Gur et al., 2017).
For the current study, participants were recruited from 6 IBBC sites
(Table 1). All participants had 22q11.2 microdeletion that was con-
ﬁrmed via the IBBC quality control procedures (i.e., whole genome se-
quencing and/or Affymetrix 6.0 microarrays as well as with available
multiplex ligation dependent probe ampliﬁcation (MLPA) and heat-
map data from microarrays) (Gur et al., 2017). Participants were in-
cluded if they underwent a comprehensive structured psychiatric as-
sessment using a validated instrument that would provide
information on ADHD diagnosis/symptoms and psychotic symptoms,
if longitudinal data were available (i.e., at least one time point follow
up of ADHD symptoms and psychotic symptoms/psychotic disorder)
and if their age at the ﬁrst-time point was ≤18 years old. This study fo-
cuses on the development of psychotic symptoms; therefore, to adopt
a clearer design, those who reported any subclinical psychoticPlease cite this article as: Niarchou, M., et al., Attention deﬁcit hyperactiv
22q11.2 deletion syndrome, Schizophr. Res. (2018), https://doi.org/10.101symptoms at T1 (n=73)were excluded from themain analyses but in-
cluded in sensitivity analyses (see statistical analyses section below).
The study was approved by the appropriate local ethics committees
and institutional review boards. Each participant and his or her care-
giver, when appropriate, provided informed written consent/assent to
participate prior to recruitment.
2.2. Psychiatric measures
Assessments were conducted using well-validated structured diag-
nostic instruments (Table 1). ADHD symptoms and diagnoses compati-
ble with DSM-IV-TR diagnostic criteria were obtained using standard
approaches for this age group -i.e., parent reported interviews. Psy-
chotic symptoms were assessed using self- and parent-reports. If either
participants or their parents reported psychotic symptoms, then these
were counted as present. We only included the positive symptoms of
psychosis in our analyses (i.e., hallucinations, delusions and thought in-
terference). Phenomena were not coded as psychotic symptoms if they
were attributed to hypnagogic and hypnopompic states, fever or sub-
stance use. Due to the different assessmentmethods and range of ques-
tions asked between the different sites, presence of any subclinical/
clinical psychotic symptom was coded as 1 (present) vs. 0 (absent), in-
stead of using a continuous scale. The ratings of psychotic disorders
were harmonized across the sites as part of the IBBC initiative (Gur
et al., 2017). Data on ADHD symptoms were also harmonized, with
sites completing information on a speciﬁc list of symptoms (Table S1).
A total inattention symptom score was obtained by summarizing the
number of inattention symptoms that were reported as present. If at
least one missing value was present, the total inattention symptom
score was reported as missing, hence the different numbers reported
for ADHD diagnosis and inattention symptoms. The primary predictor
variables were inattention symptoms (total score) and ADHD diagnosis
(present vs. absent). The outcome variables were 1. psychotic symp-
toms (present vs. absent) and 2. psychotic disorder (present vs. absent).
Psychotic disorder included schizophrenia, schizophreniform disorder,
schizoaffective disorder, psychotic disorder NOS, delusional disorder
(type or unknown), and brief psychotic disorder with at-risk status as
deﬁned by the DSM-5. For the purpose of sensitivity analyses,
hyperactive-impulsiveness and total ADHD symptom scores were also
considered as predictor variables.
2.3. Confounders
Standardized IQ scores were available across the sites using age-
appropriateWechsler scales andwere examined as confounders. Taking
into account that intellectual disability is frequently present in
22q11.2DS, some sites assessed the presence/absence of ADHD symp-
toms taking into account whether the individual with 22q11.2DS had
intellectual disability. To account for this, we included ‘site assessmentity disorder symptoms as antecedents of later psychotic outcomes in
6/j.schres.2018.07.044
3M. Niarchou et al. / Schizophrenia Research xxx (2018) xxx–xxxdifferences’ as a covariate variable.We also included age at baseline and
sex as covariates.
2.4. Statistical analyses
Logistic regressionswere conducted to examinewhether T1 inatten-
tion symptoms and ADHD diagnosis (independent variables) predicted
T2 outcome (dependent variable) status (0 = individuals without psy-
chotic symptoms, 1= individualswith psychotic symptomsand 0= in-
dividuals without psychotic disorder, 1 = individuals with psychotic
disorder). We repeated the analyses by also including age, sex, IQ and
the variable ‘site assessment differences’ (see confounders above) as co-
variates. We also examined whether longitudinal change in inattention
symptoms and ADHD diagnosis were associated with psychotic symp-
toms and/or any psychotic disorder at T2. Change in inattention symp-
toms in relation to psychotic symptoms and psychotic disorder was
examined using principal components analysis (PCA) following previ-
ously reported methods (Chawner et al., 2017; Niarchou et al., 2013).
The PCA included inattention symptoms at T1 and inattention symp-
toms at T2. Two factors were identiﬁed from the PCA, one correspond-
ing to the average of ADHD symptoms at T1 and T2 (f1) and the other
one (f2) representing change over time. Logistic regression analyses
were used to examine the associations between change over time (f2)
and psychotic symptoms/psychotic spectrum disorders at T2 after
adjusting for average ADHD symptoms (f1) as well as sex, IQ, age and
site assessment differences. The advantage of the PCA method is that
the two factors (i.e., average and change) are uncorrelated in the regres-
sion model. To examine change of ADHD diagnosis between T1 and T2
we constructed a categorical variable (presence of ADHD at neither
time point = 0, ADHD at T1 but not at T2 = 1, ADHD at T2 but not T1
= 2, ADHD at both time points = 3). Logistic regression analyses
were used where the categorical variable was the predictor and psy-
chotic symptoms/psychotic disorder were the outcome variables
while adjusting for sex, IQ, age and site assessment differences. Where
psychotic disorder was used as an outcome, due to the small sample
size of caseswith psychotic disorder, themaximum likelihood estimates
tended to inﬁnity, and in this case we used Firth's method (Firth, 1993)
instead (Heinze and Schemper, 2002). As a sensitivity analysis, we re-
peated these analyses by also examining hyperactive-impulsiveness
symptoms and total ADHD symptoms. We also examined whether
there were differences in inattention symptoms and ADHD diagnosis
in individuals who at T1 reported psychotic symptoms compared with
individuals that did not report psychotic symptoms at T1.
3. Results
3.1. Sample description
The sample started with a total of 323 individuals (49%males) aged
11.8 years at the ﬁrst assessment (SD= 3.3) and 15.1 years (SD= 4.0)
at the second assessment. Excluding 73 participants who reportedTable 2
Sample size and descriptive statistics of individuals with 22q11.2DS included in the study.
Time point 1 (T1) Time point 2
Age –T1 Age – T2 Sex
Ν Mean(SD) Mean(SD) % males
ADHD inattention symptoms 188 11.5(3.2) 14.6(3.8) 47%
N Mean(SD) Mean(SD) % males P
%
ADHD diagnosis 250 11.2(3.1) 14.3(3.6) 49% 7
Notes: N does not include individuals with psychotic symptoms at time point 1. N of individua
tention symptoms.
Abbreviations: PS = psychotic symptoms (present/absent), PSD = psychotic disorder (presen
Please cite this article as: Niarchou, M., et al., Attention deﬁcit hyperactiv
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(49% males) with complete data on psychotic symptoms and ADHD di-
agnosis and 188 individuals (47% males) with complete data on psy-
chotic symptoms and inattention symptoms (Table 2). The mean age
at assessment for individuals at T1 was 11.2 years (SD = 3.1, age
range 6 to 18) and at T2 was 14.3 years (SD = 3.6, age range 6 to 18).
The mean follow-up time across sites was 3.19 years (SD = 1.5). Of
those with psychotic symptoms at T2, 71% also had an ADHD diagnosis
at T2 and of those with psychotic disorder at T2, 63% also had an ADHD
diagnosis (Table 2).
3.2. Associations between inattention symptoms and ADHD at T1 and de-
velopment of psychosis at T2
ADHD inattention symptoms andADHDdiagnosis at T1were associ-
ated with development of psychotic symptoms at T2 (OR = 1.22, p=
0.01 and OR= 4.5, p b 0.001 respectively) (Table 3). There was no evi-
dence for associations between inattention symptoms at T1 and psy-
chotic disorder at T2 (OR = 1.18, p = 0.15). ADHD diagnosis at T1
was associated with psychotic disorder at T2 (OR = 5.92, p = 0.02)
(Table 3).
Sensitivity analyses revealed no association between T1
hyperactive-impulsiveness symptoms at T1 and psychotic symptoms
at T2 (OR = 1.15, p = 0.27) or with psychotic disorder at T2 (OR =
1.17, p=0.33) (Table S2). Therewasweak evidence for associations be-
tween total ADHD symptoms (i.e. hyperactive-impulsiveness and inat-
tention symptom scores combined) and development of T2 psychotic
symptoms (OR = 1.11, p = 0.07) but no evidence for associations
with psychotic disorder at T2 (1.10, p= 0.26) (Table S2).
As a further sensitivity analysis, we also compared individuals with
andwithout psychotic symptoms at T1 (Table S3).We found signiﬁcant
age and IQ differences, with the group reporting psychotic symptoms at
T1 being older than the groupwithout psychotic symptoms at T1 and of
lower mean IQ score. There were no signiﬁcant mean differences in
terms of inattention symptoms and ADHD diagnosis.
Table S4 shows the summary statistics for change in inattention
symptom levels and ADHD diagnosis over time in relation to psychotic
symptoms at T2. There was no evidence that change over time in inat-
tention symptom levels or ADHD diagnosis was associated with psy-
chotic symptoms or psychotic disorder at T2 (Table 4). Results were
the same for our sensitivity analyses with hyperactive-impulsive and
total ADHD symptoms (Table S5).
4. Discussion
In the largest longitudinal study examining the presence of ADHD
symptoms and diagnosis in individuals with 22q11.2DS to date, we ob-
served that inattention symptom levels and ADHD diagnosis predicted
the development of psychotic symptoms and were weakly associated
with psychotic disorder. Moreover, we found that the presence of inat-
tention symptoms at any time point rather than the change inPS (N= 45) No PS (N= 143) PSD(N = 14) No PSD (N= 174)
Mean(SD) Mean(SD) Mean(SD) Mean(SD)
5.4(2.4) 3.5(3.0) 4.9(2.2) 3.9(3.0)
S (N= 51) No PS (N= 199) PSD(N= 16) No PSD (N= 234)
% % %
1% 35% 63% 41%
ls with data on inattention symptoms is smaller because not all had information on inat-
t/absent), % = percentage of those with PS/No PS/PSD/No PSD and an ADHD diagnosis.
ity disorder symptoms as antecedents of later psychotic outcomes in
6/j.schres.2018.07.044
Table 3
ADHD symptoms/diagnosis at T1 before and after adjusting for confounders in relation to psychotic symptoms/psychotic disorder at T2.
Time point 1 Psychotic symptoms
Time point 2
Unadjusted Adjusteda Adjustedb
Odds ratio 95%CI p Odds ratio 95%CI p Odds ratio 95%CI p
ADHD inattention symptoms 1.26 1.11–1.43 b0.001 1.29 1.13–1.48 b0.001 1.22 1.06–1.41 0.01
ADHD diagnosis 4.42 2.31–8.85 b0.001 6.05 2.93–13.25 b0.001 4.45 2.09–10.08 b0.001
Time point 1 Psychotic disorder
Time point 2
Unadjusted Adjusteda Adjustedb
Odds ratio 95%CI p Odds ratio 95%CI p Odds ratio 95%CI p
ADHD inattention symptoms 1.12 0.93–1.36 0.24 1.16 0.94–1.44 0.17 1.18 0.94–1.48 0.15
ADHD diagnosis 2.40 0.86–7.25 0.10 3.61 1.21–11.8 0.03 5.92 1.52–28.56 0.02
Notes: N does not include individualswith psychotic experiences at timepoint 1. ADHD inattention symptoms andADHDdiagnosis are in separate logisticmodels. Abbreviations: ADHD=
Attention Deﬁcit Hyperactivity Disorder, a age, sex and IQ included as covariates, b age, sex, IQ and assessment differences included as covariates.
4 M. Niarchou et al. / Schizophrenia Research xxx (2018) xxx–xxxinattention symptom levels over time was associated with psychotic
symptoms. The evidence was weaker for the outcome of psychotic dis-
order, but this is likely due to low power, since in this young sample
(mean age 14.3 years) only 6%were diagnosed with psychotic disorder.
These longitudinal ﬁndings are in accordance with our previous
study that found cross-sectional associations between inattention
symptoms and psychotic symptoms in individuals with 22q11.2DS
(Niarchou et al., 2017a). Previous population-based (e.g., (Niarchou
et al., 2013)) and clinical studies (Pukrop et al., 2007) also have ob-
served that childhood inattention symptoms are an antecedent to
psychosis.Table 4
Relationship between mean levels and change over time in ADHD symptoms/diagnosis
and psychotic symptoms/psychotic disorder at T2.
Predictor variables Outcome variable: psychotic symptoms at time point 2
Average (f1) Change (f2)
Odds ratio (95%
CI)





1.51(1.05–2.22) 0.03 1.14(0.48–2.73) 0.77
Change
Odds ratio (95%CI) p-Value
ADHD diagnosis-
Categories
ADHD at T1 but not T2 3.52(0.84–14.49) 0.08
ADHD at T2 but not T1 5.74(0.64–40.0) 0.08
ADHD at both time points 9.79(3.59–30.52) b0.001
Outcome variable: psychotic disorder at time point 2
Average (f1) Change (f2)
Odds ratio (95%
CI)





1.31(0.72–2.41) 0.37 1.61(0.37–7.41) 0.53
Change
Odds ratio (95%CI) p-Value
ADHD diagnosis-
Categories
ADHD at T1 but not T2 0.65(0.00–6.69) 0.77
ADHD at T2 but not T1 1.68(0.01–21.13) 0.76
ADHD at both time points 4.76(1.37–18.91) 0.01
Notes: N does not include individuals with psychotic symptoms at time point 1, f1 = fac-
tor 1 identiﬁed from the Principal Components Analysis (PCA) and captures mean levels
across T1 and T2, f2 = factor 2 identiﬁed from the PCA and captures changes between
T1 and T2.
Please cite this article as: Niarchou, M., et al., Attention deﬁcit hyperactiv
22q11.2 deletion syndrome, Schizophr. Res. (2018), https://doi.org/10.101There are a number of potential explanations for our ﬁndings. One is
that the 22q11.2 deletion increases risk for inattention symptoms and
ADHD, which in turn increase risk for psychotic outcomes (Marsh and
Williams, 2006). Another is that inattention symptoms or an ADHD di-
agnosis in the context of 22q11.2DS are prodromal or premorbid
forms of schizophrenia rather than ADHD per se. For instance, Fletcher
and Frith (2009) suggested that psychotic symptoms are the result of
an abnormal formation of beliefs about the world (i.e., false prediction
errors). In thisway, individualswith inattention symptomsmight direct
their attention to less relevant or too many environmental cues and in
turn might perceive and interpret environmental stimuli as more un-
usual and salient, which would predispose them to having psychotic
symptoms. Therefore, these inattention symptoms might be indicators
of abnormal probabilistic learning that has been observed in schizo-
phrenia (e.g., (Reddy et al., 2016)). However, we cannot exclude the
possibility that the associations between inattention symptoms and
psychotic outcomes also reﬂect shared genetic variance, especially
given evidence for genetic overlap between ADHD and schizophrenia
(Demontis et al., 2017; Hamshere et al., 2013).
On the other hand, we did not observe cross-sectional associations
between inattention symptoms/ADHD diagnosis and psychotic symp-
toms at T1. ADHD diagnosis was equally comorbid in those with and
without psychotic symptoms and the mean levels of inattention symp-
tomswere similar between the two groups. A previous study that exam-
ined the dimensional structure of a wide spectrum of psychopathology
in 22q11.2DS has found evidence of a general psychopathology factor in
addition tomore speciﬁc factors (i.e., anxiety, mood, ADHD and psycho-
sis) (Niarchou et al., 2017b). Therefore, one potential explanation of our
ﬁndings is that at an earlier age, ADHD symptoms and psychotic symp-
toms also indicate the individual's general propensity for psychopathol-
ogy and as individuals approach the age of onset for risk of psychosis,
certain symptoms become more speciﬁc to psychosis. Finally, taking
into account that psychiatric conditions can co-occur, it may not be
ADHD per se, or any other psychiatric disorder, but rather the severity
of presentation and/or the cumulative contributions of increasing psy-
chiatric conditions/severity that increases risk for psychotic outcomes.
We did not observe association between hyperactive-impulsive
symptoms and psychotic outcomes, which accords with cross-
sectional studies of 22q11.2DS (Niarchou et al., 2017a) and
population-based studies (Hurtig et al., 2011). As has been previously
suggested (Niarchou et al., 2017a), this could be due to differences in
the way dopaminergic function acts between schizophrenia and
ADHD, with dopamine hypo-activity being more likely linked to the
hyperactivity-impulsiveness aspects of ADHD (Dichter et al., 2012)
and dopamine hyperactivity to schizophrenia (Howes and Kapur,
2009).ity disorder symptoms as antecedents of later psychotic outcomes in
6/j.schres.2018.07.044
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Our study is the ﬁrst to show that inattention symptom levels and
ADHD diagnosis in those with 22q11.2DS are associated with later
emerging psychotic outcomes. If inattention and ADHD are risk factors
for future psychosis, then effective treatment is a priority for reducing
the risk of psychosis in this high-risk group. However, if ADHD is a pro-
dromal feature of psychosis in this group, then taking into account that
stimulant medication is often prescribed for ADHD, future studies are
needed to examine potential effects of such treatment in individuals
with 22q11.2DS. A randomized controlled trial in thirty-four children
with 22q11.2DS and ADHD indicated that methylphenidate can be
safe and effective after a 6-month treatment and led to a 40% reduction
of ADHD symptoms as reported byparents (Green et al., 2011). Interest-
ingly, all subjects had at least one side effect and approximately 40% ex-
hibited depressive-like symptoms after treatment. Although
informative, the sample size as well as the follow-up time were limited
in this study. Further studies are warranted to examine the effect of
stimulants and other ADHD-treatments in 22q11.2DS.
Although the link between ADHD and psychosis is not adequately
studied (Pallanti and Salerno, 2015), our ﬁndings support those from
previous patient registry and high-risk studies in populations without
the 22q11.2 deletion that have observed associations between ADHD,
early attentional impairments and later psychosis (Dalsgaard et al.,
2014; Erlenmeyer-Kimling et al., 2000), aswell as comorbidity between
ADHD and psychosis (Levy et al., 2015). Taking into account that
22q11.2DS is a rare, large effect size mutation that serves as a powerful
model for examining early antecedents of psychosis, our ﬁndings fur-
ther point to the possibility that some patients with ADHDmight pres-
ent with psychotic symptoms at follow-up. The ﬁndings also highlight
the need for further studies in order to better understand the relation-
ship between ADHD and psychosis.4.2. Limitations
Although this study beneﬁtted from recruitment of a number of
sites of the 22q11.2 IBBC, resulting in a relatively large sample,
the study may have been underpowered for some analyses
(e.g., psychotic disorder). Moreover, the mean age at follow up was
14.3 years and therefore the individuals with 22q11.2DS had not
yet passed the peak age of onset for schizophrenia. Therefore, the as-
sociations that we report are likely to represent an underestimate.
Another limitation is that we could not consider the impact of med-
ication, since at the time of this analysis medication information was
not consistently reported from all sites. However, failing to adjust for
medication is more likely to have attenuated the magnitude of asso-
ciation between ADHD symptoms and psychotic outcomes. Although
the assessments were conducted by experienced clinicians and psy-
chologists, we cannot exclude the possibility of diverse diagnostic
practices across sites that might have inﬂuenced our ﬁndings. How-
ever, we attempted to account for differences between centres in our
analyses and did not ﬁnd that site assessment differences explained
our ﬁndings. Ascertainment bias is also likely, considering that ge-
netic testing was conducted on the basis of a phenotype that was suf-
ﬁcient to warrant genetic testing (e.g., heart defects, developmental
delay). Finally, taking into account that comorbidity is common in
22q11.2DS, it could be that other disorders (e.g., intellectual disabil-
ity, autism), in addition to ADHD, might be longitudinally associated
with psychotic outcomes in 22q11.2DS. However, this question was
outside the remits of this study. Also, it could be argued that ADHD
is more easily amenable to symptom reduction by treatment
than other potential clinical risk factors for psychosis in 22q11.2DS
(e.g. intellectual disability). Interestingly, a recent study on 89 chil-
dren with 22q11.2DS did not ﬁnd longitudinal associations between
autism spectrum disorders and psychosis (Fiksinski et al., 2017).Please cite this article as: Niarchou, M., et al., Attention deﬁcit hyperactiv
22q11.2 deletion syndrome, Schizophr. Res. (2018), https://doi.org/10.1014.3. Conclusions
Our study is the ﬁrst to examine the longitudinal associations be-
tween ADHD symptoms and psychotic outcomes in 22q11.2DS. Our
ﬁndings that inattention symptoms and ADHD diagnosis were associ-
ated with subsequent psychotic symptoms and psychotic disorder in
22q11.2DS have important clinical implications. Future studies examin-
ing the effects of ADHD medication in individuals with 22q11.2DS are
warranted.
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